Literature DB >> 30617409

MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis.

Sirio Cocozza1, Giuseppe Pontillo2, Roberta Lanzillo3, Camilla Russo2, Maria Petracca4, Martina Di Stasi2, Chiara Paolella2, Elena Augusta Vola2, Chiara Criscuolo3, Marcello Moccia3, Anna Lamberti3, Serena Monti5, Vincenzo Brescia Morra3, Andrea Elefante2, Giuseppe Palma6, Enrico Tedeschi2, Arturo Brunetti2.   

Abstract

PURPOSE: Different studies showed correlations between gadolinium-based contrast agent (GBCA) administrations and dentate nucleus (DN) T1-weighted hyperintensity. The clinical impact of gadolinium retention, however, is still largely unknown. The aim of this study was to investigate relations between MRI and clinical disability in relapsing-remitting multiple sclerosis (RR-MS) patients.
METHODS: In this retrospective study, clinical data were obtained from 74 RR-MS patients at baseline and after a mean follow-up time of 3.6 years, including the expanded disability status scale (EDSS) score and its change (ΔEDSS). Patients were considered showing clinical worsening if they score a ΔEDSS ≥ 1 (for baseline EDSS ≤ 5.5) or ΔEDSS ≥ 0.5 (for baseline EDSS > 5.5). From the MRI data, the presence of bilateral DN hyperintensity was recorded along with the calculation of longitudinal relaxation rate (R1) maps.
RESULTS: Patients with DN hyperintensity showed similar ΔEDSS change compared to those without visible changes on T1-weighted images (p = 0.32). Similarly, no DN-R1 difference was found comparing stable patients with those showing a significant clinical worsening (p = 0.54). Finally, no significant effect of DN-R1 values explained the variance in ΔEDSS (p = 0.76), thus suggesting their independence from the clinical outcome.
CONCLUSIONS: MS patients with DN hyperintensity show similar EDSS changes compared to subjects without DN high-signal intensity. Furthermore, mean DN-R1 values of patients with significant clinical worsening were comparable to those of stable subjects and were unrelated to clinical disability. Taken together, these findings suggest that gadolinium retention in the brain of MS patients does not affect their clinical worsening, expressed by the EDSS change.

Entities:  

Keywords:  EDSS; GBCA accumulation; Gadolinium-based contrast agents; Multiple sclerosis

Mesh:

Substances:

Year:  2019        PMID: 30617409     DOI: 10.1007/s00234-018-02150-4

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  14 in total

1.  Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis.

Authors:  Y Forslin; J Martola; Å Bergendal; S Fredrikson; M K Wiberg; T Granberg
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-27       Impact factor: 3.825

2.  Safety of Gadolinium-Based Contrast Agents in Patients with Stage 4 and 5 Chronic Kidney Disease: a Radiologist's Perspective.

Authors:  Erik V Soloff; Carolyn L Wang
Journal:  Kidney360       Date:  2020-01-09

3.  Unraveling Deep Gray Matter Atrophy and Iron and Myelin Changes in Multiple Sclerosis.

Authors:  G Pontillo; M Petracca; S Monti; M Quarantelli; C Criscuolo; R Lanzillo; E Tedeschi; A Elefante; V Brescia Morra; A Brunetti; S Cocozza; G Palma
Journal:  AJNR Am J Neuroradiol       Date:  2021-04-22       Impact factor: 4.966

4.  Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.

Authors:  Robert Zivadinov; Niels Bergsland; Jesper Hagemeier; Deepa P Ramasamy; Michael G Dwyer; Ferdinand Schweser; Channa Kolb; Bianca Weinstock-Guttman; David Hojnacki
Journal:  Neurology       Date:  2019-07-08       Impact factor: 11.800

5.  Dose-Lowering in Contrast-Enhanced MRI of the Central Nervous System: A Retrospective, Parallel-Group Comparison Using Gadobenate Dimeglumine.

Authors:  Mark C DeLano; Maria Vittoria Spampinato; Eric Y Chang; Richard G Barr; Richard J Lichtenstein; Cesare Colosimo; Josef Vymazal; Zhibo Wen; Doris D M Lin; Miles A Kirchin; Gianpaolo Pirovano
Journal:  J Magn Reson Imaging       Date:  2021-05-20       Impact factor: 5.119

6.  Visible T1-hyperintensity of the dentate nucleus after multiple administrations of macrocyclic gadolinium-based contrast agents: yes or no?

Authors:  Alessandra Splendiani; Antonella Corridore; Silvia Torlone; Milvia Martino; Antonio Barile; Ernesto Di Cesare; Carlo Masciocchi
Journal:  Insights Imaging       Date:  2019-09-04

7.  Macrocyclic MR contrast agents: evaluation of multiple-organ gadolinium retention in healthy rats.

Authors:  Simona Bussi; Alessandra Coppo; Roberto Celeste; Antonello Fanizzi; Alberto Fringuello Mingo; Andrea Ferraris; Catherine Botteron; Miles A Kirchin; Fabio Tedoldi; Federico Maisano
Journal:  Insights Imaging       Date:  2020-02-04

8.  Comprehensive phenotyping revealed transient startle response reduction and histopathological gadolinium localization to perineuronal nets after gadodiamide administration in rats.

Authors:  Johanna Habermeyer; Janina Boyken; Julia Harrer; Fabio Canneva; Veronika Ratz; Sandra Moceri; Jakob Admard; Nicolas Casadei; Gregor Jost; Tobias Bäuerle; Thomas Frenzel; Christoph Schmitz; Gunnar Schütz; Hubertus Pietsch; Stephan von Hörsten
Journal:  Sci Rep       Date:  2020-12-28       Impact factor: 4.379

9.  Does serial administration of gadolinium-based contrast agents affect patient neurological and neuropsychological status? Fourteen-year follow-up of patients receiving more than fifty contrast administrations.

Authors:  Josef Vymazal; Lenka Krámská; Hana Brožová; Evžen Růžička; Aaron M Rulseh
Journal:  J Magn Reson Imaging       Date:  2019-10-30       Impact factor: 4.813

10.  Prospective Multicenter Study of the Safety of Gadoteridol in 6163 Patients.

Authors:  Sung Bum Cho; A-Leum Lee; Hyuk Won Chang; Kyeong Ah Kim; Won Jong Yoo; Jeong A Yeom; Myung Ho Rho; Sung Jin Kim; Yun-Jung Lim; Miran Han
Journal:  J Magn Reson Imaging       Date:  2019-10-29       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.